COMP <GO>
KTTA vs BOLT // EV/EBITDA & P/E VALUATION
Pasithea Therapeutics Corp. (NASDAQ) VS. Bolt Biotherapeutics Inc. (NASDAQ) • 15-METRIC TALLY: KTTA 1
— BOLT 1
■ METRIC PARITY
LAST: $0.37 (-5.95%) • MKT CAP: $12.3M
valuation
—
LAST: $6.36 (-3.34%) • MKT CAP: $12.3M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KTTA VS. BOLT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KTTA | BOLT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 0.10% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 34.1 | 75.2 | -41.06 | BOLT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.3M | $12.3M | $98.4K | KTTA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KTTA REV | BOLT REV | KTTA GROSS % | BOLT GROSS % | KTTA FCF | BOLT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $7.7M | — | — | -$15.2M | -$39.9M |
| FY 2024 | $0 | $7.7M | — | — | -$13.9M | -$61.3M |
| FY 2023 | $0 | $7.9M | — | — | — | -$69.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KTTA // BETA —
BOLT // BETA —